Keytruda and Euthyrox drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Euthyrox (levothyroxine sodium). Common drug interactions include drug ineffective among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Euthyrox. It is created by eHealthMe based on reports of 44 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Euthyrox?

Euthyrox has active ingredients of levothyroxine sodium. It is often used in hypothyroidism. eHealthMe is studying from 8,740 Euthyrox users. Check the latest studies of Euthyrox.

On Jul, 18, 2026

44 people who take Keytruda and Euthyrox together, and have interactions are studied.

Keytruda and Euthyrox drug interactions.

What are the common drug interactions of Keytruda and Euthyrox, by gender? *:

female:

Drug ineffective
Dysphonia (speech disorder attributable to a disorder of phonation)
Dyspnoea (difficult or laboured respiration)
Enteritis (inflammation of the small intestine)
Erythema (redness of the skin)
Facial paralysis (loss of function of face muscle)
Gastritis (inflammation of stomach)
Headache (pain in head)
Hepatitis (inflammation of the liver)
Hypotension (abnormally low blood pressure)

male:

Nausea (feeling of having an urge to vomit)
Epistaxis (bleed from the nose)
Balance disorder
Coma (state of unconsciousness lasting more than six hours)
Contusion (a type of hematoma of tissue in which capillaries)
Death
Decreased appetite
Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)
Encephalitis autoimmune (autoimmune origin disturbances of consciousness and pyramidal signs, inflammation of the brain)

What are the common drug interactions of Keytruda and Euthyrox, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Autoimmune hepatitis
Blood bilirubin increased
Hepatic enzyme increased

50-59:

Pyrexia (fever)
Transaminases increased
Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body)
Blood pressure increased
Drug ineffective
Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
Diarrhoea
Fatigue (feeling of tiredness)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Arthralgia (joint pain)

60+:

Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Iron deficiency
Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
Malignant ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen)
Pneumonia
Pneumonia viral
Renal failure (kidney dysfunction)
Stent placement
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 6 people, 13.64%
High Blood Pressure: 6 people, 13.64%
Endometrial Cancer: 6 people, 13.64%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 9.09%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 4 people, 9.09%
Restless Leg Syndrome (a powerful urge to move your legs): 3 people, 6.82%
High Blood Cholesterol: 3 people, 6.82%
Depression: 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Euthyrox?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously